Blood Biomarker Tracks Lecanemab Response in Early Alzheimer's

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by the accumulation of amyloid‑beta and tau proteins in the brain. Lecanemab, an anti‑amyloid monoclonal antibody, has recently received regulatory approval for patients with early AD and has been shown in clinical trials to slow disease progression. The therapy is administered intravenously and is intended to reduce amyloid plaque burden, thereby slowing cognitive decline in those who meet the eligibility criteria.

Despite the demonstrated benefit, individual responses to Lecanemab vary, underscoring the need for reliable, accessible methods to monitor biological changes during treatment. Clinicians and researchers are exploring biomarkers—including cerebrospinal fluid measures, plasma amyloid‑beta levels, and neuroimaging techniques—to track therapeutic efficacy and adjust dosing or discontinue therapy when appropriate. Such monitoring tools aim to personalize care, ensuring that patients receive the most effective and safe treatment regimen.

The variability in treatment response highlights the importance of ongoing research into monitoring strategies for anti‑amyloid therapies. By integrating objective biomarkers into routine clinical practice, healthcare providers can better assess disease trajectory, optimize therapeutic outcomes, and ultimately improve the quality of life for individuals living with early Alzheimer’s disease.